ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Calliditas puts a brave face on setanaxib failure
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
Glycomimetics down and out on upro miss
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
